- Home
- ADPT vs PACS Comparison
ADPT vs PACS Comparison
Compare ADPT & PACS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- PACS
- Stock Information
- Founded
- ADPT 2009
- PACS 2013
- Country
- ADPT United States
- PACS United States
- Employees
- ADPT N/A
- PACS N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- PACS
- Sector
- ADPT Health Care
- PACS
- Exchange
- ADPT Nasdaq
- PACS Nasdaq
- Market Cap
- ADPT 1.8B
- PACS 2.0B
- IPO Year
- ADPT 2019
- PACS 2024
- Fundamental
- Price
- ADPT $10.75
- PACS $11.71
- Analyst Decision
- ADPT Strong Buy
- PACS Strong Buy
- Analyst Count
- ADPT 7
- PACS 7
- Target Price
- ADPT $10.57
- PACS $34.29
- AVG Volume (30 Days)
- ADPT 2.1M
- PACS 562.8K
- Earning Date
- ADPT 08-05-2025
- PACS 08-11-2025
- Dividend Yield
- ADPT N/A
- PACS N/A
- EPS Growth
- ADPT N/A
- PACS 82.80
- EPS
- ADPT N/A
- PACS 0.68
- Revenue
- ADPT $189,527,000.00
- PACS $3,558,953,000.00
- Revenue This Year
- ADPT $24.39
- PACS $28.62
- Revenue Next Year
- ADPT $20.44
- PACS $16.94
- P/E Ratio
- ADPT N/A
- PACS $17.24
- Revenue Growth
- ADPT 8.61
- PACS 205.08
- 52 Week Low
- ADPT $3.85
- PACS $8.28
- 52 Week High
- ADPT $12.43
- PACS $43.92
- Technical
- Relative Strength Index (RSI)
- ADPT 48.31
- PACS N/A
- Support Level
- ADPT $10.22
- PACS N/A
- Resistance Level
- ADPT $11.18
- PACS N/A
- Average True Range (ATR)
- ADPT 0.51
- PACS 0.00
- MACD
- ADPT -0.15
- PACS 0.00
- Stochastic Oscillator
- ADPT 24.82
- PACS 0.00
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About PACS PACS Group Inc. Common Stock
PACS Group Inc is a post-acute healthcare company primarily focused on delivering high-quality skilled nursing care through a portfolio of independently operated facilities Its is a nursing providers in the United States based on number of facilities, with over 200 post-acute care facilities across nine states serving over 20,000 patients daily. It also provide senior care, assisted living, and independent living options in some of communities.